The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Cell-free Tumor DNA Detection Market Research Report 2024
Synopsis
Cell-free tumor DNA (circulating tumor DNA, ctDNA) testing, the so-called "liquid biopsy". ctDNA refers to the DNA released by tumor cells into the blood circulatory system, which contains information on tumor-derived mutations and gene variations. ctDNA is a tumor marker with broad application prospects, high sensitivity and high specificity, and is suitable for a variety of tumors, providing an opportunity for non-invasive sampling of tumors.
Global Cell-free Tumor DNA Detection market is projected to reach US$ 9170.5 million in 2029, increasing from US$ 5150 million in 2022, with the CAGR of 8.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Cell-free Tumor DNA Detection market research.
Key companies engaged in the Cell-free Tumor DNA Detection industry include Biocept Inc., Bio-Rad Laboratories Inc., Fluxion Biosciences Inc., F. Hoffmann-La Roche AG, Sysmex Europe SE, Qiagen, NeoGenomics Laboratories Inc., Menarini Silicon Biosystems and Illumina Inc., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Cell-free Tumor DNA Detection were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Cell-free Tumor DNA Detection market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Cell-free Tumor DNA Detection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Biocept Inc.
Bio-Rad Laboratories Inc.
Fluxion Biosciences Inc.
F. Hoffmann-La Roche AG
Sysmex Europe SE
Qiagen
NeoGenomics Laboratories Inc.
Menarini Silicon Biosystems
Illumina Inc.
Guardant Health Inc.
Shanghai Biotecan Medical Diagnostics Co.,Ltd.
Segment by Type
Droplet Digital Polymerase Chain Reaction
Tagged-Amplicon Deep Sequencing
Others
Segment by Application
Breast Cancer
Stomach Cancer
Liver Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Cell-free Tumor DNA Detection report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Cell-free tumor DNA (circulating tumor DNA, ctDNA) testing, the so-called "liquid biopsy". ctDNA refers to the DNA released by tumor cells into the blood circulatory system, which contains information on tumor-derived mutations and gene variations. ctDNA is a tumor marker with broad application prospects, high sensitivity and high specificity, and is suitable for a variety of tumors, providing an opportunity for non-invasive sampling of tumors.
Global Cell-free Tumor DNA Detection market is projected to reach US$ 9170.5 million in 2029, increasing from US$ 5150 million in 2022, with the CAGR of 8.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Cell-free Tumor DNA Detection market research.
Key companies engaged in the Cell-free Tumor DNA Detection industry include Biocept Inc., Bio-Rad Laboratories Inc., Fluxion Biosciences Inc., F. Hoffmann-La Roche AG, Sysmex Europe SE, Qiagen, NeoGenomics Laboratories Inc., Menarini Silicon Biosystems and Illumina Inc., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Cell-free Tumor DNA Detection were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Cell-free Tumor DNA Detection market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Cell-free Tumor DNA Detection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Biocept Inc.
Bio-Rad Laboratories Inc.
Fluxion Biosciences Inc.
F. Hoffmann-La Roche AG
Sysmex Europe SE
Qiagen
NeoGenomics Laboratories Inc.
Menarini Silicon Biosystems
Illumina Inc.
Guardant Health Inc.
Shanghai Biotecan Medical Diagnostics Co.,Ltd.
Segment by Type
Droplet Digital Polymerase Chain Reaction
Tagged-Amplicon Deep Sequencing
Others
Segment by Application
Breast Cancer
Stomach Cancer
Liver Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Cell-free Tumor DNA Detection report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cell-free Tumor DNA Detection Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Droplet Digital Polymerase Chain Reaction
1.2.3 Tagged-Amplicon Deep Sequencing
1.2.4 Others
1.3 Market by Application
1.3.1 Global Cell-free Tumor DNA Detection Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Breast Cancer
1.3.3 Stomach Cancer
1.3.4 Liver Cancer
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cell-free Tumor DNA Detection Market Perspective (2018-2029)
2.2 Cell-free Tumor DNA Detection Growth Trends by Region
2.2.1 Global Cell-free Tumor DNA Detection Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Cell-free Tumor DNA Detection Historic Market Size by Region (2018-2023)
2.2.3 Cell-free Tumor DNA Detection Forecasted Market Size by Region (2024-2029)
2.3 Cell-free Tumor DNA Detection Market Dynamics
2.3.1 Cell-free Tumor DNA Detection Industry Trends
2.3.2 Cell-free Tumor DNA Detection Market Drivers
2.3.3 Cell-free Tumor DNA Detection Market Challenges
2.3.4 Cell-free Tumor DNA Detection Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cell-free Tumor DNA Detection Players by Revenue
3.1.1 Global Top Cell-free Tumor DNA Detection Players by Revenue (2018-2023)
3.1.2 Global Cell-free Tumor DNA Detection Revenue Market Share by Players (2018-2023)
3.2 Global Cell-free Tumor DNA Detection Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cell-free Tumor DNA Detection Revenue
3.4 Global Cell-free Tumor DNA Detection Market Concentration Ratio
3.4.1 Global Cell-free Tumor DNA Detection Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cell-free Tumor DNA Detection Revenue in 2022
3.5 Cell-free Tumor DNA Detection Key Players Head office and Area Served
3.6 Key Players Cell-free Tumor DNA Detection Product Solution and Service
3.7 Date of Enter into Cell-free Tumor DNA Detection Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cell-free Tumor DNA Detection Breakdown Data by Type
4.1 Global Cell-free Tumor DNA Detection Historic Market Size by Type (2018-2023)
4.2 Global Cell-free Tumor DNA Detection Forecasted Market Size by Type (2024-2029)
5 Cell-free Tumor DNA Detection Breakdown Data by Application
5.1 Global Cell-free Tumor DNA Detection Historic Market Size by Application (2018-2023)
5.2 Global Cell-free Tumor DNA Detection Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Cell-free Tumor DNA Detection Market Size (2018-2029)
6.2 North America Cell-free Tumor DNA Detection Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Cell-free Tumor DNA Detection Market Size by Country (2018-2023)
6.4 North America Cell-free Tumor DNA Detection Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cell-free Tumor DNA Detection Market Size (2018-2029)
7.2 Europe Cell-free Tumor DNA Detection Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Cell-free Tumor DNA Detection Market Size by Country (2018-2023)
7.4 Europe Cell-free Tumor DNA Detection Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cell-free Tumor DNA Detection Market Size (2018-2029)
8.2 Asia-Pacific Cell-free Tumor DNA Detection Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Cell-free Tumor DNA Detection Market Size by Region (2018-2023)
8.4 Asia-Pacific Cell-free Tumor DNA Detection Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cell-free Tumor DNA Detection Market Size (2018-2029)
9.2 Latin America Cell-free Tumor DNA Detection Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Cell-free Tumor DNA Detection Market Size by Country (2018-2023)
9.4 Latin America Cell-free Tumor DNA Detection Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cell-free Tumor DNA Detection Market Size (2018-2029)
10.2 Middle East & Africa Cell-free Tumor DNA Detection Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Cell-free Tumor DNA Detection Market Size by Country (2018-2023)
10.4 Middle East & Africa Cell-free Tumor DNA Detection Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Biocept Inc.
11.1.1 Biocept Inc. Company Detail
11.1.2 Biocept Inc. Business Overview
11.1.3 Biocept Inc. Cell-free Tumor DNA Detection Introduction
11.1.4 Biocept Inc. Revenue in Cell-free Tumor DNA Detection Business (2018-2023)
11.1.5 Biocept Inc. Recent Development
11.2 Bio-Rad Laboratories Inc.
11.2.1 Bio-Rad Laboratories Inc. Company Detail
11.2.2 Bio-Rad Laboratories Inc. Business Overview
11.2.3 Bio-Rad Laboratories Inc. Cell-free Tumor DNA Detection Introduction
11.2.4 Bio-Rad Laboratories Inc. Revenue in Cell-free Tumor DNA Detection Business (2018-2023)
11.2.5 Bio-Rad Laboratories Inc. Recent Development
11.3 Fluxion Biosciences Inc.
11.3.1 Fluxion Biosciences Inc. Company Detail
11.3.2 Fluxion Biosciences Inc. Business Overview
11.3.3 Fluxion Biosciences Inc. Cell-free Tumor DNA Detection Introduction
11.3.4 Fluxion Biosciences Inc. Revenue in Cell-free Tumor DNA Detection Business (2018-2023)
11.3.5 Fluxion Biosciences Inc. Recent Development
11.4 F. Hoffmann-La Roche AG
11.4.1 F. Hoffmann-La Roche AG Company Detail
11.4.2 F. Hoffmann-La Roche AG Business Overview
11.4.3 F. Hoffmann-La Roche AG Cell-free Tumor DNA Detection Introduction
11.4.4 F. Hoffmann-La Roche AG Revenue in Cell-free Tumor DNA Detection Business (2018-2023)
11.4.5 F. Hoffmann-La Roche AG Recent Development
11.5 Sysmex Europe SE
11.5.1 Sysmex Europe SE Company Detail
11.5.2 Sysmex Europe SE Business Overview
11.5.3 Sysmex Europe SE Cell-free Tumor DNA Detection Introduction
11.5.4 Sysmex Europe SE Revenue in Cell-free Tumor DNA Detection Business (2018-2023)
11.5.5 Sysmex Europe SE Recent Development
11.6 Qiagen
11.6.1 Qiagen Company Detail
11.6.2 Qiagen Business Overview
11.6.3 Qiagen Cell-free Tumor DNA Detection Introduction
11.6.4 Qiagen Revenue in Cell-free Tumor DNA Detection Business (2018-2023)
11.6.5 Qiagen Recent Development
11.7 NeoGenomics Laboratories Inc.
11.7.1 NeoGenomics Laboratories Inc. Company Detail
11.7.2 NeoGenomics Laboratories Inc. Business Overview
11.7.3 NeoGenomics Laboratories Inc. Cell-free Tumor DNA Detection Introduction
11.7.4 NeoGenomics Laboratories Inc. Revenue in Cell-free Tumor DNA Detection Business (2018-2023)
11.7.5 NeoGenomics Laboratories Inc. Recent Development
11.8 Menarini Silicon Biosystems
11.8.1 Menarini Silicon Biosystems Company Detail
11.8.2 Menarini Silicon Biosystems Business Overview
11.8.3 Menarini Silicon Biosystems Cell-free Tumor DNA Detection Introduction
11.8.4 Menarini Silicon Biosystems Revenue in Cell-free Tumor DNA Detection Business (2018-2023)
11.8.5 Menarini Silicon Biosystems Recent Development
11.9 Illumina Inc.
11.9.1 Illumina Inc. Company Detail
11.9.2 Illumina Inc. Business Overview
11.9.3 Illumina Inc. Cell-free Tumor DNA Detection Introduction
11.9.4 Illumina Inc. Revenue in Cell-free Tumor DNA Detection Business (2018-2023)
11.9.5 Illumina Inc. Recent Development
11.10 Guardant Health Inc.
11.10.1 Guardant Health Inc. Company Detail
11.10.2 Guardant Health Inc. Business Overview
11.10.3 Guardant Health Inc. Cell-free Tumor DNA Detection Introduction
11.10.4 Guardant Health Inc. Revenue in Cell-free Tumor DNA Detection Business (2018-2023)
11.10.5 Guardant Health Inc. Recent Development
11.11 Shanghai Biotecan Medical Diagnostics Co.,Ltd.
11.11.1 Shanghai Biotecan Medical Diagnostics Co.,Ltd. Company Detail
11.11.2 Shanghai Biotecan Medical Diagnostics Co.,Ltd. Business Overview
11.11.3 Shanghai Biotecan Medical Diagnostics Co.,Ltd. Cell-free Tumor DNA Detection Introduction
11.11.4 Shanghai Biotecan Medical Diagnostics Co.,Ltd. Revenue in Cell-free Tumor DNA Detection Business (2018-2023)
11.11.5 Shanghai Biotecan Medical Diagnostics Co.,Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
